It has been reported that FoxP3, similar to the function of the PD-1/PD-L1 signaling pathway, may also inhibit T cell function and participate in immune evasion, thereby promoting cancer initiation and progression, while also contributing to resistance to targeted therapies such as PD-1/PD-L1 inhibitors [37, 38]. The gene discussed is PDCD1; the disease is cancer.